Cardiologist impressed by experimental pill that significantly lowers cholesterol
An experimental oral PCSK9 inhibitor is associated with LDL-C reductions that could prove to be a game-changer for patient care.
An experimental oral PCSK9 inhibitor is associated with LDL-C reductions that could prove to be a game-changer for patient care.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
